Vancampfort · The American journal of psychiatry 2013 · systematic review and meta-analysis · n=6,983 participants across 37 publications (81 articles)

Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators.

Cited 443 times in the scientific literature.

Level 3 - non-randomized controlled study

Systematic review and meta-analysis of observational studies

PubMed 23361837 · doi:10.1176/appi.ajp.2012.12050620 · record verified 2026-08-28

What was done

The authors conducted a systematic review and meta-analysis of studies in MEDLINE, PsycINFO, EMBASE, and CINAHL up to April 2012 to determine the prevalence and moderators of metabolic syndrome in patients with bipolar disorder. They calculated pooled prevalence using standardized criteria, evaluated odds compared to general population controls, and assessed moderators including age, geographic region, and antipsychotic treatment.

What was found

Across 81 articles in 37 publications comprising 6,983 participants: - The overall pooled metabolic syndrome rate was 37.3% (95% CI: 36.1% to 39.0%). - Bipolar patients had significantly higher odds of metabolic syndrome than general population groups (OR = 1.98, 95% CI: 1.74 to 2.25). - Geographic region was the strongest moderator, with the highest rates reported in New Zealand and Australia (64.2%, 95% CI: 38.3% to 83.9%) and North America (49.3%, 95% CI: 29.7% to 69.3%); older age had a modest effect. - Patients currently treated with antipsychotics had higher metabolic syndrome rates (45.3%, 95% CI: 39.6% to 50.9%) than those who were antipsychotic-free (32.4%, 95% CI: 27.5% to 37.4%; OR = 1.72, 95% CI: 1.24 to 2.38).

Why it matters

These findings show that more than a third of patients with bipolar disorder meet criteria for metabolic syndrome—nearly double the rate of the general population—highlighting the need for routine metabolic monitoring and cardio-preventive care, especially in patients receiving antipsychotics.

Limits

The included studies are observational, which limits causal inference regarding medication use or disease mechanisms. The abstract does not report data on specific antipsychotic agents, dosages, duration of treatment, lifestyle confounders, or variations between different definitions of metabolic syndrome.

Cited by